Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause
Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause
复制标题
DOI：
10.1002/(sici)1097-0142(19980815)83:4
复制
发表时间：
1998-08-15
期刊：
影响因子：
6.2
通讯作者：
Grenier, J
中科院分区：
文献类型：
--
作者：
Pujol, P;Daures, JP;Grenier, J
背景，乳腺癌手术时雌激素受体（ER）和孕激素受体（PgR）状态被用作预后和激素依赖性的标志物，以指导辅助治疗。作者研究了手术时激素环境对 ER 和 PgR 水平的影响。方法。对 2020 名乳腺癌患者（其中包括 575 名绝经前女性）进行了分析。 ER 和 PgR 水平通过放射性配体结合测定测定（截止值，10 fmol/mg）。手术当天获得的血清雌二醇 (E2)、黄体酮 (Pg)、卵泡刺激素 (FSH) 和黄体生成素 (LH) 水平用于定义绝经前的月经周期阶段。 结果，在绝经前，卵泡期 (62%，n = 316) 的 ER 阳性 (ER+) 肿瘤比例高于排卵期（51%，n = 59）和黄体期（53%，n = 200，P = 0.03）。卵泡期的平均 ER 水平 (30 fmol/mg) 也高于排卵期 (20 fmol/mg) 和黄体期 (25 fmol/mg, P < 0.001)。 PgR 阳性 (PgR(+)) 肿瘤的百分比在排卵期 (85%) 往往高于卵泡期 (78%) 和黄体期 (72%) (P = 0.11)。排卵期的平均 PgR（177 fmol/mg）也高于卵泡期和黄体期（分别为 134 和 92 fmol/mg；P < 0.001）。绝经期女性中 ER+ 肿瘤的比例高于绝经前女性（分别为 67% 和 59%；P < 0.001）。相反，绝经期女性中 PgR(+) 肿瘤的比例低于绝经前女性（分别为 65% 和 78%；P < 0.001）。在绝经前，ER 和 E2 水平之间存在弱负相关。在绝经前和绝经期妇女中，ER 和 Pg 水平与 FSH 和 LH 水平之间，或者 PgR 与 E2、Pg、FSH 和 LH 水平之间没有相关性。结论，月经周期和绝经期间乳腺癌中 ER 和 PgR 水平的变化表明，根据类固醇受体值解释激素依赖性应考虑手术时的激素状态。癌症 1998；83：698-705，(C) 1998 美国癌症协会。
BACKGROUND, Estrogen receptor (ER) and progesterone receptor (PgR) status at the time of breast carcinoma surgery is used as a marker of both prognosis and hormone dependency to guide adjuvant therapy. The authors studied the influence of hormonal milieu at the time of surgery on ER and PgR levels.METHODS. A population of 2020 patients with breast carcinoma, including 575 premenopausal women, was analyzed. ER and PgR levels were determined by radioligand binding assays (cutoff values, 10 fmol/mg). Serum estradiol (E2), progesterone (Pg), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) levels obtained on the day of surgery were used to define the menstrual cycle phase in premenopause.RESULTS, In premenopause, there was a higher proportion of ER positive (ER+) tumors in the follicular phase (62%, n = 316) than in the ovulatory phase (51%, n = 59) and the luteal phase (53%, n = 200, P = 0.03). The mean ER level was also higher in the follicular phase (30 fmol/mg) than in the ovulatory phase (20 fmol/mg) and the luteal phase (25 fmol/mg, P < 0.001). The percentage of PgR positive (PgR(+)) tumors tended to be higher in the ovulatory phase (85%) than in the follicular (78%) and luteal (72%) phases (P = 0.11). The mean PgR was also higher in the ovulatory phase (177 fmol/mg) than in the follicular and luteal phases (134 and 92 fmol/mg, respectively; P < 0.001). The percentage of ER+ tumors was higher among menopausal women than among premenopausal women (67% vs. 59%, respectively; P < 0.001). Conversely, the percentage of PgR(+) tumors was lower among menopausal women than among premenopausal women (65% vs. 78%, respectively; P < 0.001). In premenopause, there was a weak negative correlation between ER and E2 levels. No correlations were found between levels of ER and Pg and levels of FSH and LH or among levels of PgR and E2, Pg, and FSH and LH in premenopausal and menopausal women.CONCLUSIONS, Changes in ER and PgR levels in breast carcinoma during the menstrual cycle and menopause suggest that interpretations of hormone dependency on the basis of steroid receptor values should take into account hormonal status at the time of surgery. Cancer 1998;83:698-705, (C) 1998 American Cancer Society.